Canna~Fangled Abstracts

The endocannabinoid system as a target for addiction treatment: Trials and tribulations.

By May 28, 2017 No Comments
Neuropharmacology. 2017 May 28. pii: S0028-3908(17)30256-3. doi: 10.1016/j.neuropharm.2017.05.031.
[Epub ahead of print]

Abstract

pm-2-site-207Addiction remains a major public health concern, and while pharmacotherapies can be effective, clinicians are limited by the paucity of existing interventions. Endocannabinoid signaling is involved in reward and addiction, which raises the possibility that drugs targeting this system could be used to treat substance use disorders. This review discusses findings from randomized controlled trials evaluating cannabinergic medications for addiction. Current evidence suggests that pharmacotherapies containing delta-9-tetrahydrocannabinol, such as dronabinol and nabiximols, are effective for cannabis withdrawal. Dronabinol may also reduce symptoms of opioid withdrawal. The cannabinoid receptor 1 (CB1) inverse agonist rimonabant showed promising effects for smoking cessation but also caused psychiatric side effects and currently lacks regulatory approval. Few trials have investigated cannabinergic medications for alcohol use disorder. Overall, the endocannabinoid system remains a promising target for addiction treatment. Development of novel medications such as fatty acid amide hydrolase inhibitors and neutral CB1 antagonists promises to extend the range of available interventions.

KEYWORDS:

Cannabidiol; Cannabinoid antagonists; Clinical trial; Dronabinol; Endocannabinoids; Smoking cessation; Substance use disorders; Withdrawal

PMID: 28564576

 

DOI: 10.1016/j.neuropharm.2017.05.031

Publication type

Publication type

twin memes II
en English